Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the ...

We recently published 10 Stocks Exploded Over 100%; One Shockingly Soared 11,000%. Verona Pharma plc (NASDAQ:VRNA) is one of ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

U.S.-listed shares of Verona Pharma ( VRNA) soared to an all-time high Wednesday after Merck ( MRK) agreed to pay about $10 ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...